AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Beyfortus (nirsevimab by Year
Beyfortus (nirsevimab — direct product sales) — Worldwide product sales ($M) ($M)
AstraZeneca Beyfortus (nirsevimab: $281M in FY2025, down 11.6% from a year earlier.
Where the FY2025 figure comes from
“|| Beyfortus | 281 | (12) | (12) | 184 | (21) | - | - | - | 94 | 12 | 12 | 3 | 58 | 53”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Beyfortus (nirsevimab — direct product sales) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 281 | -11.6% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 318 | +200.0% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 106 | – | Form 6-K FY2023Q4 Earnings Release ↗ |
Breakdown
What makes up beyfortus (nirsevimab
- Beyfortus (nirsevimab — direct product sales) — Worldwide YoY actual (%)-12.0% · FY2025
- Beyfortus (nirsevimab — direct product sales) — Worldwide YoY CER (%)-12.0% · FY2025
- Beyfortus (nirsevimab — direct product sales) — US product sales ($M)184 · FY2025
- Beyfortus (nirsevimab — direct product sales) — Emerging Markets product sales ($M)0 · FY2025
- Beyfortus (nirsevimab — direct product sales) — Europe product sales ($M)94 · FY2025
- Beyfortus (nirsevimab — direct product sales) — Established RoW product sales ($M)3 · FY2025
Cite this data
StockData. (2026). AstraZeneca Beyfortus (nirsevimab ($M), annual FY2023–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-beyfortus-world
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.